- Home
- BJRI vs ARDX Comparison
BJRI vs ARDX Comparison
Compare BJRI & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- ARDX
- Stock Information
- Founded
- BJRI 1978
- ARDX 2007
- Country
- BJRI United States
- ARDX United States
- Employees
- BJRI N/A
- ARDX N/A
- Industry
- BJRI Restaurants
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- ARDX Health Care
- Exchange
- BJRI Nasdaq
- ARDX Nasdaq
- Market Cap
- BJRI 983.0M
- ARDX 882.9M
- IPO Year
- BJRI 1996
- ARDX 2014
- Fundamental
- Price
- BJRI $35.43
- ARDX $4.24
- Analyst Decision
- BJRI Hold
- ARDX Strong Buy
- Analyst Count
- BJRI 5
- ARDX 9
- Target Price
- BJRI $41.40
- ARDX $10.17
- AVG Volume (30 Days)
- BJRI 534.6K
- ARDX 3.9M
- Earning Date
- BJRI 07-31-2025
- ARDX 08-04-2025
- Dividend Yield
- BJRI N/A
- ARDX N/A
- EPS Growth
- BJRI N/A
- ARDX N/A
- EPS
- BJRI 0.95
- ARDX N/A
- Revenue
- BJRI $1,367,941,000.00
- ARDX $361,706,000.00
- Revenue This Year
- BJRI $5.58
- ARDX $11.39
- Revenue Next Year
- BJRI $2.93
- ARDX $32.84
- P/E Ratio
- BJRI $38.56
- ARDX N/A
- Revenue Growth
- BJRI 2.91
- ARDX 127.33
- 52 Week Low
- BJRI $27.61
- ARDX $3.21
- 52 Week High
- BJRI $47.02
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- BJRI 25.95
- ARDX 49.07
- Support Level
- BJRI $35.99
- ARDX $4.21
- Resistance Level
- BJRI $39.24
- ARDX $4.47
- Average True Range (ATR)
- BJRI 1.31
- ARDX 0.18
- MACD
- BJRI -0.52
- ARDX -0.04
- Stochastic Oscillator
- BJRI 6.24
- ARDX 5.94
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.